Park, Ji Hyun
Ahn, Jin-Hee
Kim, Sung-Bae
Clinical trials referenced in this document:
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba502
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
https://doi.org/10.1186/s12935-019-0793-2
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention
https://doi.org/10.1080/14728222.2019.1570499
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba502
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
https://doi.org/10.1200/jco.23.01214
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.
https://doi.org/10.1200/jco.2024.42.16_suppl.1021
Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype
https://doi.org/10.1136/esmoopen-2020-000984
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
https://doi.org/10.1200/jco.23.01214
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.
https://doi.org/10.1200/jco.2024.42.16_suppl.1021
Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype
https://doi.org/10.1136/esmoopen-2020-000984
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Is the NCI MATCH trial a match for gynecologic oncology?
https://doi.org/10.1016/j.ygyno.2015.11.003
Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
https://doi.org/10.1136/bmjopen-2022-061334
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
https://doi.org/10.1200/jco.2024.42.16_suppl.582
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
https://doi.org/10.1200/po-24-00776
Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
https://doi.org/10.1200/jco.2023.41.16_suppl.611
Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL.
https://doi.org/10.1200/jco.2024.42.16_suppl.597
Study designs for clinical trials applied to personalised medicine: a scoping review
https://doi.org/10.1136/bmjopen-2021-052926
Current Challenges in Cancer Treatment
https://doi.org/10.1016/j.clinthera.2016.03.026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors
https://doi.org/10.1136/bmjonc-2025-001037
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2014.08.006
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
https://doi.org/10.1200/jco.2023.41.16_suppl.514
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba612
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba509
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba520
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.594
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.10600
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
https://doi.org/10.1007/s10549-024-07555-9
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
https://doi.org/10.1200/jco.2024.42.23_suppl.1
A review of phase II trial designs for initial marker validation
https://doi.org/10.1016/j.cct.2013.05.001
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
https://doi.org/10.1136/jitc-2020-002179
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.584
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
https://doi.org/10.1200/jco.2023.41.16_suppl.102
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2015.08.002
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba501
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
https://doi.org/10.1200/jco.2024.42.16_suppl.601
Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
https://doi.org/10.1200/op.2023.19.11_suppl.369
Documents that mention this clinical trial
Emerging strategies for targeting PI3K in gynecologic cancer
https://doi.org/10.1016/j.ygyno.2015.09.083
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
PARP inhibitors in ovarian cancer: Current status and future promise
https://doi.org/10.1016/j.ygyno.2014.02.039
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Is the NCI MATCH trial a match for gynecologic oncology?
https://doi.org/10.1016/j.ygyno.2015.11.003
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
https://doi.org/10.1200/jco.2023.41.16_suppl.3112
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
https://doi.org/10.1200/po.22.00421
PIK3CB Inhibitor GSK2636771 in Cancers With
<i>PTEN</i>
Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
https://doi.org/10.1200/po-25-00265
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
https://doi.org/10.1200/po-24-00451
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
https://doi.org/10.1200/jco.2023.41.16_suppl.3108
Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis
https://doi.org/10.1136/bmj-2021-067745
Phase II Study of Sunitinib in Tumors With
<i>c-KIT</i>
Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
https://doi.org/10.1200/po-24-00514
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Activating HER2 mutations as emerging targets in multiple solid cancers
https://doi.org/10.1136/esmoopen-2017-000279
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib
https://doi.org/10.1016/j.lungcan.2015.10.025
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
https://doi.org/10.1136/bcr-2020-236242
Novel therapeutics in low-grade serous ovarian cancer
https://doi.org/10.1136/ijgc-2022-003677
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
https://doi.org/10.1136/esmoopen-2019-000515
Documents that mention this clinical trial
Is the NCI MATCH trial a match for gynecologic oncology?
https://doi.org/10.1016/j.ygyno.2015.11.003
Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
https://doi.org/10.1136/bmjopen-2022-061334
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
https://doi.org/10.1200/jco.2024.42.16_suppl.582
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
https://doi.org/10.1200/po-24-00776
Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
https://doi.org/10.1200/jco.2023.41.16_suppl.611
Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL.
https://doi.org/10.1200/jco.2024.42.16_suppl.597
Study designs for clinical trials applied to personalised medicine: a scoping review
https://doi.org/10.1136/bmjopen-2021-052926
Current Challenges in Cancer Treatment
https://doi.org/10.1016/j.clinthera.2016.03.026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors
https://doi.org/10.1136/bmjonc-2025-001037
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2014.08.006
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
https://doi.org/10.1200/jco.2023.41.16_suppl.514
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba612
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba509
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba520
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.594
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.10600
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
https://doi.org/10.1007/s10549-024-07555-9
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
https://doi.org/10.1200/jco.2024.42.23_suppl.1
A review of phase II trial designs for initial marker validation
https://doi.org/10.1016/j.cct.2013.05.001
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
https://doi.org/10.1136/jitc-2020-002179
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.584
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
https://doi.org/10.1200/jco.2023.41.16_suppl.102
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2015.08.002
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba501
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
https://doi.org/10.1200/jco.2024.42.16_suppl.601
Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
https://doi.org/10.1200/op.2023.19.11_suppl.369
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
https://doi.org/10.1136/jitc-2021-sitc2021.338
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
https://doi.org/10.1186/s13058-024-01946-y
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
https://doi.org/10.1136/jitc-2020-002100
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
515 Tumor agnostic spatially defined immune cell gene signatures predict immunotherapy outcomes
https://doi.org/10.1136/jitc-2025-sitc2025.0515
Documents that mention this clinical trial
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba500
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
This article is maintained by: Elsevier
Article Title: How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Journal Title: ESMO Open
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/esmoopen-2018-000357
Content Type: article
Copyright: © 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.